{
    "ticker": "PASG",
    "name": "Passage Bio, Inc.",
    "description": "Passage Bio, Inc. is a clinical-stage gene therapy company focused on developing transformative genetic medicines for patients with serious, life-threatening disorders. Founded in 2019 and headquartered in Philadelphia, Pennsylvania, Passage Bio harnesses the power of adeno-associated virus (AAV) gene therapy to create innovative treatments for neurological diseases, with a specific emphasis on pediatric patients. The company's lead product candidate, PBFT02, is designed to treat GM1 gangliosidosis, a rare genetic disorder that leads to progressive neurological decline. Through its proprietary platform, Passage Bio aims to leverage its expertise in AAV technology to overcome the challenges faced in treating genetic disorders of the central nervous system. The company is committed to advancing its pipeline and collaborating with academic and industry partners to enhance the development of its therapies. With a strong focus on patient needs, Passage Bio is dedicated to bringing hope and healing to families affected by rare genetic conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Philadelphia, Pennsylvania, USA",
    "founded": "2019",
    "website": "https://www.passagebio.com",
    "ceo": "Dr. Benjamin Hwang",
    "social_media": {
        "twitter": "https://twitter.com/PassageBio",
        "linkedin": "https://www.linkedin.com/company/passage-bio"
    },
    "investor_relations": "https://investors.passagebio.com",
    "key_executives": [
        {
            "name": "Dr. Benjamin Hwang",
            "position": "CEO"
        },
        {
            "name": "Dr. Steven Gray",
            "position": "Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "PBFT02"
            ]
        }
    ],
    "seo": {
        "meta_title": "Passage Bio, Inc. | Gene Therapy for Neurological Disorders",
        "meta_description": "Explore Passage Bio, Inc., a clinical-stage gene therapy company dedicated to developing innovative treatments for serious genetic disorders. Learn about our mission and pipeline.",
        "keywords": [
            "Passage Bio",
            "Gene Therapy",
            "Neurological Disorders",
            "GM1 Gangliosidosis",
            "AAV Gene Therapy"
        ]
    },
    "faq": [
        {
            "question": "What is Passage Bio known for?",
            "answer": "Passage Bio is known for its clinical-stage gene therapies targeting neurological disorders."
        },
        {
            "question": "Who is the CEO of Passage Bio?",
            "answer": "Dr. Benjamin Hwang is the CEO of Passage Bio, Inc."
        },
        {
            "question": "Where is Passage Bio headquartered?",
            "answer": "Passage Bio is headquartered in Philadelphia, Pennsylvania, USA."
        },
        {
            "question": "What is Passage Bio's lead product candidate?",
            "answer": "The lead product candidate is PBFT02, aimed at treating GM1 gangliosidosis."
        },
        {
            "question": "When was Passage Bio founded?",
            "answer": "Passage Bio was founded in 2019."
        }
    ],
    "competitors": [
        "BMRN",
        "SNY",
        "AVRO"
    ],
    "related_stocks": [
        "VRTX",
        "REGN",
        "NVS",
        "AMGN"
    ]
}